Cormedix (CRMD) shares jumped 8% pre-market after Q3 results topped estimates, and the company raised full-year revenue guidance to $390–$410 million. The strong performance was fueled by higher DefenCath use among dialysis patients. EPS came in at $1.26, doubling expectations, with 2025 EBITDA projected between $220–$240 million.